Today: 19 May 2026
KLA stock drops again as chip-equipment names slide; what’s driving KLAC now

KLA stock drops again as chip-equipment names slide; what’s driving KLAC now

New York, Feb 4, 2026, 12:54 EST — Regular session underway.

  • KLA shares dropped roughly 4% by midday, deepening their recent multi-day slide.
  • Applied Materials and Lam Research, both chip-equipment makers, also fall amid the broader tech sell-off.
  • With U.S. labor and inflation data pushed back, investors are zeroing in on upcoming industry events for signs of demand.

KLA Corp (KLAC.O) shares dropped 4.4%, hitting $1,295.70 by midday Wednesday, deepening losses in chip-equipment stocks. So far, the stock has fluctuated between $1,294.65 and $1,375.89 during the session.

The stock slipped again after two straight drops this week, now off roughly 23% from its 52-week peak on Jan. 29. KLA finished Tuesday down 3.9% and lost 1.2% on Monday.

Why this matters now: chipmaking-tool stocks have started trading like high-beta tech once more, showing sharp moves as investors react to changing forecasts for 2026 fab capacity spending. KLA, a major supplier of process control equipment—the inspection and measurement gear that chipmakers rely on to boost yields and spot defects—often sees its shares swing in line with sentiment on cutting-edge production.

Wednesday’s decline coincided with turmoil across tech stocks. The S&P 500 and Nasdaq slipped, while the Dow inched higher. Investors remain unsettled by a selloff hitting software and cloud segments, alongside pressure on chipmakers after AMD warned of a drop in quarterly revenue. “We’re a bit bearish on software in general,” said Josh Chastant, portfolio manager at GuideStone Funds, citing concerns that AI could disrupt established business models. Reuters

KLA wasn’t the only one taking a hit. Applied Materials (AMAT.O) dropped 9.0%, Lam Research (LRCX.O) plunged 10.6%, and ASML (ASML.O) slipped 5.3% during the same session.

The pullback arrived despite some analysts maintaining a positive outlook following last week’s earnings. Citigroup’s Atif Malik held a “Buy” rating and bumped up his price target on KLA to $1,800, a report published Tuesday shows. GuruFocus

Last week, KLA topped Wall Street’s revenue and profit forecasts for the quarter, projecting March-quarter sales around $3.35 billion, plus or minus $150 million. Still, shares slipped after the announcement. Michael Ashley Schulman of Running Point Capital Advisors noted the stock “had already sprinted into the print,” cautioning that KLA’s outlook suggested “steady growth rather than renewed acceleration.” Reuters

Still, the risks linger. Post-earnings, some analysts flagged supply bottlenecks and extended lead times that could slow KLA’s shipment growth at the start of the year. UBS’s Timothy Arcuri noted that “during good times it can’t ramp as fast,” while Needham’s Charles Shi warned it’s “too early to call a race.” Barron’s

Macro factors have resurfaced for rate-sensitive tech stocks. The U.S. Bureau of Labor Statistics announced the delayed January employment report will drop next Wednesday, Feb. 11. Meanwhile, January’s CPI is now scheduled for Friday, Feb. 13, and the postponed JOLTS report will come out Thursday, Feb. 5.

KLA is set for a busy February with several industry events on its calendar, including SEMICON Korea from Feb. 11 to 13 and SPIE Advanced Lithography + Patterning running Feb. 22 to 26. These gatherings often draw attention from traders seeking hints on demand and delivery trends, particularly as customers finalize their capital spending plans for 2026.

Tech’s tone this week has hinged on earnings and forward guidance, pushing major indexes mostly down in Wednesday’s trading. Investors now seek a fresh catalyst. For KLA, that probably comes down to whether upcoming macro data and mid-February industry reports can shore up risk appetite in chip tools.

Stock Market Today

  • Diploma Share Prices Surge After Boosting 2026 Guidance
    May 19, 2026, 4:24 AM EDT. Diploma, an industrial-supply firm, raised its fiscal 2026 expectations for the second time following stronger-than-expected first-half results. The company reported higher revenue and key earnings metrics, prompting a positive market reaction. The guidance lift reflects confidence in continued growth amid robust demand.

Latest articles

HIVE Stock Up 29% While Nasdaq Moves Lower as Traders Eye AI Gigafactory

HIVE Stock Up 29% While Nasdaq Moves Lower as Traders Eye AI Gigafactory

19 May 2026
HIVE Digital Technologies closed at $3.46 on Nasdaq Monday, up 28.6%, and rose to $3.59 after hours following news of a planned 320 MW AI data center near Toronto targeting over 100,000 GPUs. The project is expected to cost C$3.5 billion and open in late 2027. Shares of other crypto miners fell as bitcoin traded near $77,142.
Ameren Holders Approve CEO Compensation, $14 Million Package Not Unanimous

Ameren Holders Approve CEO Compensation, $14 Million Package Not Unanimous

19 May 2026
Ameren shareholders approved executive pay, re-elected the full board, and ratified PwC as auditor. CEO Martin J. Lyons, Jr.’s 2025 compensation rose to $14.06 million, up from $9.73 million the previous year. The “say-on-pay” proposal received over 208 million votes in favor. Ameren shares last traded at $107.38, up $1.02.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 19.05.2026

19 May 2026
Warner Bros. Discovery shares traded at $27.10 on May 19, about 10% below some intrinsic value estimates but above a cited fair value of $18.17. The company reported $37.2 billion in annual revenue and a $1.7 billion loss. Analysts remain split on valuation amid merger talks with Paramount and ongoing regulatory uncertainty. Discounted cash flow models value the stock at $30.04.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Tesla stock slides nearly 5% as China sales and Model Y pricing collide with a tech-led selloff
Previous Story

Tesla stock slides nearly 5% as China sales and Model Y pricing collide with a tech-led selloff

SoFi stock tumbles in regular session as post-upgrade bounce fades — what to watch next
Next Story

SoFi stock tumbles in regular session as post-upgrade bounce fades — what to watch next

Go toTop